FOR IMMEDIATE RELEASE
April 14, 2008
Contact: Byron Myers
805.562.0503

SANTA BARBARA, CA - Medical device manufacturer Inogen, Inc., a pioneer in portable oxygen therapy, announced today that Heath Lukatch, Ph.D. has been appointed Chairman of the company's Board of Directors. Dr. Lukatch, a partner of Novo A/S San Francisco office, brings significant operational and financial management experience to Inogen.

"Inogen's management is very excited that Heath has accepted a bigger role with the company. His extensive experience in Healthcare, both as a Board member as well as a CEO, is a great asset for the company. I personally am grateful to be able to work closer with Heath in the future," said Ray Huggenberger, CEO of Inogen.

"With its innovative market-leading portable oxygen concentrator, Inogen has a bright future ahead," said Dr Lukatch. "Novo A/S is pleased to be involved with a company of this caliber, and I personally look forward to working with Inogen’s management team and other Board members as the company moves into a rapid growth phase."

Dr. Lukatch has extensive healthcare venture investing experience. He joined and opened Novo Ventures San Francisco office in 2006, was a founding partner of SightLine Partners, and was managing director at Piper Jaffray Ventures. Heath has invested in multiple medical device and biotechnology companies. In addition to Inogen, Heath also currently serves as a director at Synosia Therapeutics, Amira Pharmaceuticals, AnaptysBio and he is chairman of the board at NeuroTherapeutics Pharma.

Prior to his involvement in venture capital, Dr. Lukatch worked as a strategy consultant with McKinsey & Company, serving a range of large and small healthcare clients. Before joining McKinsey, he was founder and CEO of AutoMate Scientific, a San Francisco-based biotechnology instrumentation manufacturer and marketer. In addition, Dr. Lukatch was a bench scientist at Chiron, Cetus and Roche Bioscience in the areas of molecular biology, protein chemistry and electrophysiology, respectively.

Heath earned his Ph.D. in Neuroscience with emphasis in Pharmacology from Stanford University and his undergraduate degree with high honors in Biochemistry from the University of California at Berkeley.